Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use

Immune checkpoint inhibitors (ICIs) have transformed the landscape of solid cancer management. These drugs carry a risk of novel side effects, which have become known as immune-related adverse events (irAEs). Traditionally, irAEs have been managed empirically with corticosteroids. A subset of these...

Descripción completa

Detalles Bibliográficos
Autores principales: Haider, Sana, Chua, Wei, Balakrishnar, Bavanthi, Della-Fiorentina, Stephen, Roberts, Tara Laurine, Keat, Karuna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668263/
http://dx.doi.org/10.1136/jitc-2023-007885

Ejemplares similares

Ejemplares similares